Form 8-K - Current report:
SEC Accession No. 0001193125-25-118882
Filing Date
2025-05-13
Accepted
2025-05-13 16:49:23
Documents
14
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d918635d8k.htm   iXBRL 8-K 24965
2 EX-99.1 d918635dex991.htm EX-99.1 42598
  Complete submission text file 0001193125-25-118882.txt   197641

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA spro-20250513.xsd EX-101.SCH 2869
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20250513_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20250513_pre.xml EX-101.PRE 11274
16 EXTRACTED XBRL INSTANCE DOCUMENT d918635d8k_htm.xml XML 3635
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 25940981
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)